Combination therapy has transformed treatment for advanced thyroid cancers, especially aggressive anaplastic thyroid cancer (ATC) and radioiodine-refractory differentiated thyroid cancer (DTC). By targeting multiple pathways at once, these approaches overcome resistance and significantly improve patient outcomes compared with traditional single therapies.
A major advance is the FDA-approved combination of dabrafenib and trametinib for BRAF V600E–mutated cancers, now a standard of care with improved survival. Emerging strategies combine targeted therapy with immunotherapy, such as atezolizumab or pembrolizumab, showing encouraging survival and enabling surgery in some cases. Other combinations include chemotherapy with lenvatinib and novel pairings with RET inhibitors.
Future treatment is shifting toward personalized, biomarker-driven care based on mutations like BRAF and RET. New immunotherapies and multimodal strategies integrating surgery and radiation are under study, offering renewed hope for patients with these difficult cancers.